Propanc Biopharma, Inc. current report, 23 December 2020

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Propanc Biopharma, Inc. on December 23, 2020. The company is incorporated in Delaware and maintains its principal executive offices in Camberwell, Australia. The report details significant changes to the company's executive leadership and Board of Directors effective December 23, 2020.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.

Material Changes

  • Resignation of Officer: Carlo Campiciano resigned as Chief Financial Officer (CFO) and Secretary, effective December 23, 2020. He also relinquished his role as the Principal Financial and Accounting Officer. The filing states there was no disagreement or dispute regarding his resignation.
  • Appointment of Officer: James Nathanielsz, the company's Chief Executive Officer (CEO), assumed the additional duties of CFO and was designated as the Principal Financial and Accounting Officer effective December 23, 2020.
  • Election of Director: Josef Zelinger, age 70, was appointed to the Board of Directors effective December 23, 2020. Mr. Zelinger is a Certified Practicing Accountant with 45 years of experience in tax, auditing, finance, and management consulting.

Guidance, Outlook, and Compensation

The filing does not provide financial guidance, outlook, or management commentary on business operations. Regarding compensation, Mr. Zelinger entered into a Director Agreement entitling him to $250 AUD per month, subject to adjustment at the company's discretion. The company also entered into an Indemnification Agreement with Mr. Zelinger.

Investor Verification Checklist

  • Verify the dual role of James Nathanielsz as both CEO and CFO and assess potential conflicts of interest or resource constraints.
  • Review the full text of the Director Agreement (Exhibit 10.1) and Indemnification Agreement (Exhibit 10.2) attached to the filing.
  • Confirm the company's current liquidity status, as the departure of the CFO may impact financial reporting timelines or capital raising efforts.
  • Check subsequent filings for the appointment of a new Secretary, as the previous Secretary resigned alongside the CFO.